13,104 Shares in Fresenius Medical Care AG (NYSE:FMS) Bought by Callan Capital LLC

Callan Capital LLC purchased a new position in shares of Fresenius Medical Care AG (NYSE:FMS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,104 shares of the company’s stock, valued at approximately $297,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Venturi Wealth Management LLC boosted its position in Fresenius Medical Care by 8.4% in the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock valued at $129,000 after buying an additional 441 shares during the last quarter. Allworth Financial LP boosted its position in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after buying an additional 581 shares during the last quarter. MML Investors Services LLC boosted its position in Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock valued at $320,000 after buying an additional 753 shares during the last quarter. DAVENPORT & Co LLC boosted its position in Fresenius Medical Care by 1.5% in the 4th quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company’s stock valued at $1,316,000 after buying an additional 862 shares during the last quarter. Finally, Crossmark Global Holdings Inc. boosted its position in Fresenius Medical Care by 2.2% in the 4th quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company’s stock valued at $1,456,000 after buying an additional 1,398 shares during the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Performance

Shares of FMS stock opened at $23.09 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $25.25. The company’s 50-day simple moving average is $23.41 and its 200-day simple moving average is $21.68. The stock has a market capitalization of $13.55 billion, a price-to-earnings ratio of 19.08, a PEG ratio of 0.76 and a beta of 0.93.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on FMS shares. Truist Financial upped their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday, January 6th. StockNews.com raised shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Berenberg Bank started coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target on the stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.